- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01496625
National Eye Institute Biorepository for Retinal Diseases
NEI Intramural Biorepository for Retinal Diseases
Background:
- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some people respond to treatment while others do not. Researchers want to collect physical samples and personal data to develop a National Eye Institute database.
Objectives:
- To collect health information and blood and tissue samples from people with and without eye diseases, to be used in research studies.
Eligibility:
- Individuals of any age with different types of eye disease.
- Healthy volunteers with no history of eye disease.
Design:
- Participants may be recruited from National Eye Institute studies or may be referred from other sources.
- Participants will be screened with a physical exam and medical history. They will also have a full eye exam. Questions will be asked about family medical history, especially about eye disease.
- Blood samples will be collected. Other samples, such as saliva, tears, hair, stool, and urine, may be collected as needed. Adult participants may also provide a skin sample.
- Tissue or fluid from eye collected as part of eye care or treatment may also be added to the database.
- No treatment will be provided as part of this study.
Study Overview
Status
Detailed Description
This protocol establishes a clinical database and biospecimen repository for potential use in subsequent research projects approved by the NIH IRB, such as the identification of novel factors relevant to the pathogenesis, progression, and response to treatment of a variety of retinal conditions, particularly age-related macular degeneration (AMD) and diabetic retinopathy and their associated systemic correlates of disease.
Objectives: This protocol provides for standardized collection of longitudinal clinical data and for serial collection, processing, and storage of a variety of biospecimens. The clinical data set and biospecimen repository may be used in subsequent potential research studies for purposes including identification of novel genetic factors, biomarkers, and experimental models associated with pathogenesis, progression, and response to treatment for various conditions of the retina and their associated systemic correlates of disease.
Study Population: We plan to accrue up to 200 participants with AMD, 125 participants with diabetic retinopathy, 200 participants with other retinal diseases, and 125 participants without any retinal disease. A total of up to 650 participants may be enrolled.
Design: This protocol is designed around prospective observation of multiple retinal diseases and suitable controls incorporating:
Defined testing and ocular imaging on a standardized follow-up schedule; and
Collection of biospecimens for research purposes for which sampling does not incur more than minimal risk to participants.
Outcome Measures: Potential outcome measures for subsequent studies using this data set may include the interaction of key parameters of phenotype (such as visual acuity and retinal features on ocular imaging) with genetic variants and other biomarkers identified from biospecimens, and the characterization of new experimental models of eye health and disease.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Cathy Kangale-Whitney, R.N.
- Phone Number: (301) 402-4174
- Email: cathy.kangale-whitney@nih.gov
Study Contact Backup
- Name: Tiarnan DL Keenan, M.D.
- Phone Number: (301) 451-6330
- Email: tiarnan.keenan@nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Recruiting
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- Phone Number: TTY dial 711 800-411-1222
- Email: ccopr@nih.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
- INCLUSION CRITERIA:
Participants will be eligible if they:
- Have the ability to understand and sign an informed consent or have a parent/legal guardian to do so if they are minor children.
- Manifest diagnosed or undiagnosed retinal disease(s), or could serve as an unaffected control suitable for comparison to participants with various retinal diseases, particularly AMD and diabetic retinopathy (taking into account matching factors such as age and past ocular history).
EXCLUSION CRITERIA:
Participants will not be eligible if they:
- Are unable or unwilling to give informed consent that includes collection and study of at least one peripheral blood sample.
- Are unable or unwilling to give informed consent that includes use of NIH medical records and clinical samples for research.
- Have a systemic disease that compromises the ability to provide adequate ophthalmologic examination or treatment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Cohort 1
Participants with age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases.
|
Cohort 2
Participants without any retinal diseases.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interaction of key parameters of phenotype with genetic variants, and characterization of new experimental models of eye health and disease.
Time Frame: Ongoing
|
Potential outcome measures for subsequent studies using this data set may include the interaction of key parameters of phenotype (such as visual acuity and retinal features on ocular imaging) with genetic variants and other biomarkers identified from biospecimens, and the characterization of new experimental models of eye health and disease.
|
Ongoing
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tiarnan DL Keenan, M.D., National Eye Institute (NEI)
Publications and helpful links
General Publications
- Wiggs JL. Genomic promise: personalized medicine for ophthalmology. Arch Ophthalmol. 2008 Mar;126(3):422-3. doi: 10.1001/archopht.126.3.422. No abstract available.
- Baird PN, Hageman GS, Guymer RH. New era for personalized medicine: the diagnosis and management of age-related macular degeneration. Clin Exp Ophthalmol. 2009 Nov;37(8):814-21. doi: 10.1111/j.1442-9071.2009.02136.x.
- Brooks BP, Macdonald IM, Tumminia SJ, Smaoui N, Blain D, Nezhuvingal AA, Sieving PA; National Ophthalmic Disease Genotyping Network (eyeGENE). Genomics in the era of molecular ophthalmology: reflections on the National Ophthalmic Disease Genotyping Network (eyeGENE). Arch Ophthalmol. 2008 Mar;126(3):424-5. doi: 10.1001/archopht.126.3.424. No abstract available.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Eye Diseases
- Endocrine System Diseases
- Congenital Abnormalities
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Retinal Degeneration
- Genetic Diseases, Inborn
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Abnormalities, Multiple
- Neurocutaneous Syndromes
- Ciliopathies
- Angiomatosis
- Macular Degeneration
- Retinal Diseases
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Von Hippel-Lindau Disease
Other Study ID Numbers
- 120042
- 12-EI-0042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn